Generic drug

Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in Germany

Retrieved on: 
Wednesday, January 31, 2024
Multiple sclerosis, DMTS, Natalizumab, RRMS, Medicine, Patient, Nerve, Endocrinology, Neurology, Generic drug

53 SIX Swiss Exchange Listing Rules

Key Points: 
  • 53 SIX Swiss Exchange Listing Rules
    Basel, January 31, 2024 – Sandoz, the global leader in generic and biosimilar medicines, today announces the launch of Tyruko® (natalizumab) in Germany from February 1.
  • Developed by Polpharma Biologics, Tyruko® is the first and only biosimilar to treat RRMS.
  • Rebecca Guntern, President Europe, Sandoz, said: “Early treatment with disease-modifying therapies can have a significant impact on people living with multiple sclerosis and their potential future disabilities.
  • Through an exclusive global license, Sandoz has the rights to commercialize and distribute it in all markets.

Domrex Pharma Inc. Expands Presence in the United States

Retrieved on: 
Thursday, February 1, 2024
Diabetes, Hospitals, Health, Pharmaceutical, Medical Supplies, Acceleration, Patient, Pharmacy, Business development, Hospital, Generic drug

Domrex Pharma Inc., a leading manufacturer and distributor of medical supplies in Canada, is thrilled to announce the acceleration of its expansion into the United States.

Key Points: 
  • Domrex Pharma Inc., a leading manufacturer and distributor of medical supplies in Canada, is thrilled to announce the acceleration of its expansion into the United States.
  • This significant move involves the establishment of Domrex Pharma USA Inc., with its headquarters strategically located in Florida.
  • Originating in Quebec, Domrex Pharma has successfully extended its reach to hospitals, pharmacies, clinics, and long-term care facilities across Canada.
  • Domrex Pharma USA Inc. boasts a cutting-edge logistics solution designed to streamline operations, ensuring prompt and reliable distribution of medical supplies.

11.24% CAGR Growth in Transportation Management Systems (TMS) Market by Solution (on-premise and cloud-based), mode of transportation (roadways, railways, and airways), and Region - Global Forecast to 2027 - Technavio

Retrieved on: 
Friday, February 2, 2024
Cloud, Carriageway, Growth, RFID, Risk management, Care Act 2014, USD, Challenge, Automated guided vehicle, TMS, EDI, GPS, Affordable Care Act, AGV, Organization, Generic drug

NEW YORK, Feb. 1, 2024 /PRNewswire/ -- The transportation management systems (TMS) market is estimated to grow by USD 3.70 billion from 2022 to 2027, according to Technavio.

Key Points: 
  • NEW YORK, Feb. 1, 2024 /PRNewswire/ -- The transportation management systems (TMS) market is estimated to grow by USD 3.70 billion from 2022 to 2027, according to Technavio.
  • North America is expected to contribute 37% to the global TMS market growth during the forecast period.
  • These systems streamline freight management, fleet management, and shipment tracking, optimizing routes and enhancing warehouse and inventory management.
  • The Fleet Telematics Systems Market size is forecast to increase by USD 88.48 billion, at a CAGR of 23.87% between 2023 and 2028.

Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US market

Retrieved on: 
Monday, January 22, 2024
Paratriathlon, Patient, Novartis, USD, Ophthalmology, Generic drug

53 SIX Swiss Exchange Listing Rules

Key Points: 
  • 53 SIX Swiss Exchange Listing Rules
    Basel, January 22, 2024 – Sandoz, the global leader in generic and biosimilar medicines, has signed an agreement to acquire the US biosimilar ranibizumab CIMERLI®* (ranibizumab-eqrn) from Coherus BioSciences, Inc. for an upfront cash purchase payment of USD 170 million.
  • This is inclusive of a biologics license application, product inventory, ophthalmology sales and field reimbursement talent, as well as access to proprietary commercial software.
  • Keren Haruvi, President Sandoz North America, said: “I am pleased that we can add another high-value product to the growing Sandoz biosimilar portfolio, further strengthening our existing ophthalmology franchise.
  • The agreement to acquire the CIMERLI®* business from Coherus allows us to build a more robust ophthalmic platform that would support future product launches.

Eagle Pharmaceuticals Provides Update on Bendamustine Intellectual Property Portfolio

Retrieved on: 
Thursday, January 18, 2024
District court, Orange Book, Manager, Interim, The Orange Book, Patent, Generic drug

WOODCLIFF LAKE, N.J., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today provided an update on its bendamustine intellectual property portfolio.

Key Points: 
  • WOODCLIFF LAKE, N.J., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today provided an update on its bendamustine intellectual property portfolio.
  • Eagle is also announcing that the U.S. Patent and Trademark Office has granted U.S. Patent Nos.
  • 11844783 (the “‘783 patent”) and 11872214 (the “‘214 patent”) covering Eagle’s innovative bendamustine liquid formulations.
  • Eagle cannot predict the timing or ultimate outcome of the litigation described above or the impact of this litigation on its business.

Global Generic Drugs Market Report 2024 - Increasing Patent Cliffs and Exclusivities, Favorable Regulatory Policies, and Positive Changes in Prescription Patterns are Driving Market Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 24, 2024
Health, Pharmaceutical, Plasma protein binding, Patient, Cancer, ESG, Prevalence, Growth, Generic drug

The global market for generic drugs was valued at $407.2 billion in 2022.

Key Points: 
  • The global market for generic drugs was valued at $407.2 billion in 2022.
  • The increasing patent cliffs and exclusivities, favorable regulatory policies, and positive changes in prescription patterns are responsible for market growth.
  • This report segments the global market by molecule type and region.
  • The report discusses the current size and growth of the market for generic drugs, both in global terms and broken down by the most important national markets.

Samsung Bioepis Releases First Quarter 2024 US Biosimilar Market Report

Retrieved on: 
Wednesday, January 17, 2024
Patient, ASP, Adalimumab, Acquisition, Market access, CMS, WAC, Generic drug

Report highlights latest biosimilar pricing and market share status, including state of the adalimumab market

Key Points: 
  • Report highlights latest biosimilar pricing and market share status, including state of the adalimumab market
    INCHEON, Korea, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. today released its First Quarter 2024 Biosimilar Market Report which provides most timely information on the current status of biosimilars in the United States.
  • The report also dives into the current state of the adalimumab market, providing insights on how the underutilization of adalimumab biosimilars is delaying the opportunity for cost savings for the US healthcare system.
  • “Despite entry of multiple adalimumab biosimilars in July, the adoption remains stagnant at 2.0% after 6 months.
  • Samsung Bioepis Biosimilar Market Report, which was first published in April 2023, is being published every quarter after the CMS publishes updated ASP values for each product.

YARAL Pharma Marks Its First Anniversary

Retrieved on: 
Tuesday, January 9, 2024
General Health, Pharmaceutical, Health, CCO, Government, Drawing, AG, Pharmacy, IBSA, Generic drug

YARAL Pharma Inc. , (YARAL Pharma) is proud to celebrate the first anniversary of its entry into the United States generics marketplace.

Key Points: 
  • YARAL Pharma Inc. , (YARAL Pharma) is proud to celebrate the first anniversary of its entry into the United States generics marketplace.
  • YARAL Pharma is the U.S. generics subsidiary of IBSA (Institut Biochimique SA), a distinguished multinational pharmaceutical company headquartered in Lugano, Switzerland.
  • "Our journey over the past year has been marked by significant accomplishments," said Stephen Beckman, CEO of YARAL Pharma.
  • “In a changing generics industry landscape, YARAL Pharma remains resilient and continues to thrive,” added Beckman.

ARCHIMEDES ANNOUNCES BIOSIMILARS FIRST™, AN INDUSTRY LEADING PROGRAM TO DRIVE BIOSIMILAR ADOPTION IN 2024

Retrieved on: 
Thursday, January 11, 2024
WAC, PBM, Patient, Publishing, Social media, Pharmacy, FDA, Physician, Generic drug

BRENTWOOD, Tenn., Jan. 11, 2024 /PRNewswire/ -- Archimedes, a recognized leader in specialty drug management solutions, announced BiosimilarsFirst™, a program, which excludes Humira from formulary in favor of low cost, low WAC biosimilars.

Key Points: 
  • BRENTWOOD, Tenn., Jan. 11, 2024 /PRNewswire/ -- Archimedes, a recognized leader in specialty drug management solutions, announced BiosimilarsFirst™, a program, which excludes Humira from formulary in favor of low cost, low WAC biosimilars.
  • BiosimilarsFirst is projected to drive industry-leading adoption of biosimilars for autoimmune diseases, providing plan sponsor savings of 65% plus and more affordable treatment options for patients.
  • Archimedes' BiosimilarsFirst program stands in direct contrast to the PBM market's approach by preferring low cost biosimilars and excluding both brand and high cost biosimilars.
  • As evidence to this, Archimedes' Biosimilar Fill Rate™ was 94% in 2023 for drugs that had a biosimilar available throughout all of 2023.

Kirby McInerney LLP Announces Pendency of Class Action and Proposed Settlement Involving Purchasers of Reata Pharmaceuticals, Inc. Common Stock

Retrieved on: 
Monday, January 8, 2024
Prejudice, Claim, Action, Clerk, Agreement, Person, Court, CLASS, Notice, Hearing, Reata Pharmaceuticals, ARE, READ, Release, Lawsuit, Class Action, Settlement, Lasso, Counsel, District court, Motion, Certification, Generic drug

PLEASE READ THIS NOTICE CAREFULLY, YOUR RIGHTS WILL BE AFFECTED BY A CLASS ACTION LAWSUIT PENDING IN THIS COURT.

Key Points: 
  • PLEASE READ THIS NOTICE CAREFULLY, YOUR RIGHTS WILL BE AFFECTED BY A CLASS ACTION LAWSUIT PENDING IN THIS COURT.
  • YOU ARE ALSO NOTIFIED that Lead Plaintiff in the Action has reached a proposed settlement of the Action for $45,000,000 in cash (the "Settlement"), that, if approved, will resolve all claims in the Action.
  • If you are a member of the Settlement Class, your rights will be affected by the pending Action and the Settlement, and you may be entitled to share in the Settlement Fund.
  • All questions about this notice, the proposed Settlement, or your eligibility to participate in the Settlement, should be directed to Lead Counsel or the Claims Administrator.